Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes
Abstract Stem cell derived insulin producing cells or islets have shown promise in reversing Type 1 Diabetes (T1D), yet successful transplantation currently necessitates long‐term modulation with immunosuppressant drugs. An alternative approach to avoiding this immune response is to utilize an islet...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202100820 |
id |
doaj-4cf0798c8ca246f8b21fe8ecf5742881 |
---|---|
record_format |
Article |
spelling |
doaj-4cf0798c8ca246f8b21fe8ecf57428812021-08-18T18:34:55ZengWileyAdvanced Science2198-38442021-08-01816n/an/a10.1002/advs.202100820Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 DiabetesDebkalpa Goswami0Daniel A. Domingo‐Lopez1Niamh A. Ward2Jeffrey R. Millman3Garry P. Duffy4Eimear B. Dolan5Ellen T. Roche6Institute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge MA 02139 USADepartment of Anatomy College of Medicine, Nursing, and Health Sciences National University of Ireland Galway Galway H91 TK33 IrelandDepartment of Biomedical Engineering School of Engineering College of Science and Engineering National University of Ireland Galway Galway H91 TK33 IrelandDivision of Endocrinology, Metabolism & Lipid Research Washington University School of Medicine St. Louis MO 63110 USADepartment of Anatomy College of Medicine, Nursing, and Health Sciences National University of Ireland Galway Galway H91 TK33 IrelandDepartment of Biomedical Engineering School of Engineering College of Science and Engineering National University of Ireland Galway Galway H91 TK33 IrelandInstitute for Medical Engineering and Science Massachusetts Institute of Technology Cambridge MA 02139 USAAbstract Stem cell derived insulin producing cells or islets have shown promise in reversing Type 1 Diabetes (T1D), yet successful transplantation currently necessitates long‐term modulation with immunosuppressant drugs. An alternative approach to avoiding this immune response is to utilize an islet macroencapsulation device, where islets are incorporated into a selectively permeable membrane that can protect the transplanted cells from acute host response, whilst enabling delivery of insulin. These macroencapsulation systems have to meet a number of stringent and challenging design criteria in order to achieve the ultimate goal of reversing T1D. In this progress report, the design considerations and functional requirements of macroencapsulation systems are reviewed, specifically for stem‐cell derived islets (SC‐islets), highlighting distinct design parameters. Additionally, a perspective on the future for macroencapsulation systems is given, and how incorporating continuous sensing and closed‐loop feedback can be transformative in advancing toward an autonomous biohybrid artificial pancreas.https://doi.org/10.1002/advs.202100820implantable therapeutic devicesmacroencapsulation devicesstem cell derived isletstype 1 diabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Debkalpa Goswami Daniel A. Domingo‐Lopez Niamh A. Ward Jeffrey R. Millman Garry P. Duffy Eimear B. Dolan Ellen T. Roche |
spellingShingle |
Debkalpa Goswami Daniel A. Domingo‐Lopez Niamh A. Ward Jeffrey R. Millman Garry P. Duffy Eimear B. Dolan Ellen T. Roche Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes Advanced Science implantable therapeutic devices macroencapsulation devices stem cell derived islets type 1 diabetes |
author_facet |
Debkalpa Goswami Daniel A. Domingo‐Lopez Niamh A. Ward Jeffrey R. Millman Garry P. Duffy Eimear B. Dolan Ellen T. Roche |
author_sort |
Debkalpa Goswami |
title |
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes |
title_short |
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes |
title_full |
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes |
title_fullStr |
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes |
title_full_unstemmed |
Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes |
title_sort |
design considerations for macroencapsulation devices for stem cell derived islets for the treatment of type 1 diabetes |
publisher |
Wiley |
series |
Advanced Science |
issn |
2198-3844 |
publishDate |
2021-08-01 |
description |
Abstract Stem cell derived insulin producing cells or islets have shown promise in reversing Type 1 Diabetes (T1D), yet successful transplantation currently necessitates long‐term modulation with immunosuppressant drugs. An alternative approach to avoiding this immune response is to utilize an islet macroencapsulation device, where islets are incorporated into a selectively permeable membrane that can protect the transplanted cells from acute host response, whilst enabling delivery of insulin. These macroencapsulation systems have to meet a number of stringent and challenging design criteria in order to achieve the ultimate goal of reversing T1D. In this progress report, the design considerations and functional requirements of macroencapsulation systems are reviewed, specifically for stem‐cell derived islets (SC‐islets), highlighting distinct design parameters. Additionally, a perspective on the future for macroencapsulation systems is given, and how incorporating continuous sensing and closed‐loop feedback can be transformative in advancing toward an autonomous biohybrid artificial pancreas. |
topic |
implantable therapeutic devices macroencapsulation devices stem cell derived islets type 1 diabetes |
url |
https://doi.org/10.1002/advs.202100820 |
work_keys_str_mv |
AT debkalpagoswami designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT danieladomingolopez designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT niamhaward designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT jeffreyrmillman designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT garrypduffy designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT eimearbdolan designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes AT ellentroche designconsiderationsformacroencapsulationdevicesforstemcellderivedisletsforthetreatmentoftype1diabetes |
_version_ |
1721202641024843776 |